Target Indication Insights Why did the type 2 diabetes segment dominate the obesity GLP-1 market
This is an important question, and we're glad you're thinking about it
First, individual-level data from a large consortium of prospective, population-based studies (Supplemental Table 1) was used to build a statistical model estimating the probability of incident CVD and mortality from 5 prespecified CVD risk factors that were modified by GLP-1RAs in the SELECT trial: body weight (ie, BMI), glycemic status (ie, glycosylated hemoglobin [HbA 1c ]), hypertension (ie, systolic blood pressure), hyperlipidemia (ie, nonhigh-density-lipoprotein [HDL] cholesterol), and inflammatory burden (ie, high-sensitivity C-reactive protein [hsCRP])
aeruginosa can hinder the filamentation of C
Novo Nordisks liraglutide, indicated for weight loss as Saxenda and for Type 2 diabetes as Victoza, has been on the list since July 2023